Literature DB >> 26923184

SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.

Fengbo Yu1, Guihong Li2, Junxia Gao3, Yuxue Sun2, Pengfei Liu2, Haijun Gao2, Peiwen Li2, Ting Lei2, Yong Chen2, Ye Cheng2, Xiao Zhai4, Arash J Sayari5, Haiyan Huang2, Qingchun Mu6.   

Abstract

OBJECTIVES: Glioblastoma multiforme (GBM) is the most aggressive brain tumour type in humans. Its poor prognosis is largely attributed to its invasiveness and high rate of recurrence. Recurring GBM is commonly resistant to chemotherapeutic drugs, making it specially difficult to treat. Recent studies have revealed that matricellular glycoprotein SPOCK1 to be upregulated in several cancer types and to be specifically expressed in invasive GBM, but not in other types of non-invasive brain tumour, which prompted us to study the mechanism of action of SPOCK1 in invasion, recurrence and drug resistance of GBM cells.
MATERIALS AND METHODS: SPOCK1 expression in GBM tissues was evaluated using qPCR, Western blotting and immunohistochemical staining. Cell migration was tested by the wound healing method and cell invasion was assessed using transwell plates with Matrigel coating. Western blotting was performed for E-cadherin, vimentin, N-cadherin, p-Akt and Akt. Cell viability was examined using the MTT assay.
RESULTS: We found that the expression of SPOCK1 was significantly upregulated in recurrent GBM. We also demonstrated that SPOCK1 positively regulated migration, invasion and EMT process of GBM cells. Furthermore, SPOCK1 mediated TMZ resistance in GBM, as knockdown of SPOCK1 expression in TMZ-resistant GBM cells substantially sensitized these cells to TMZ.
CONCLUSION: SPOCK1 results were positive and it mediated TMZ resistance in GBM. In addition, SPOCK1 regulated invasion and TMZ resistance in GBM cells via the Akt signalling pathway.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26923184      PMCID: PMC6496696          DOI: 10.1111/cpr.12241

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  25 in total

Review 1.  Akt signaling: linking membrane events to life and death decisions.

Authors:  B A Hemmings
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

2.  Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.

Authors:  Carolin Kubelt; Kirsten Hattermann; Susanne Sebens; H Maximilian Mehdorn; Janka Held-Feindt
Journal:  Int J Oncol       Date:  2015-03-31       Impact factor: 5.650

3.  SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.

Authors:  Yan Li; Leilei Chen; Tim Hon Man Chan; Ming Liu; Kar-Lok Kong; Ji-Liang Qiu; Yan Li; Yun-Fei Yuan; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2012-09-25       Impact factor: 22.682

4.  Temozolomide: mechanisms of action, repair and resistance.

Authors:  Jihong Zhang; Malcolm F G Stevens; Tracey D Bradshaw
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 5.  New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

Authors:  Amir R Dehdashti; Monika E Hegi; Luca Regli; Alessia Pica; Roger Stupp
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

6.  Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.

Authors:  Qingchun Mu; Lijun Wang; Fengbo Yu; Haijun Gao; Ting Lei; Peiwen Li; Pengfei Liu; Xu Zheng; Xitong Hu; Yong Chen; Zhenfeng Jiang; Arash J Sayari; Jia Shen; Haiyan Huang
Journal:  Cancer Biol Ther       Date:  2015-02-26       Impact factor: 4.742

7.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Authors:  Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 8.  SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target.

Authors:  Jianguo Feng; Liling Tang
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

9.  SPOCK1 is a novel transforming growth factor-β target gene that regulates lung cancer cell epithelial-mesenchymal transition.

Authors:  Liyun Miao; Yongsheng Wang; Hongping Xia; Chengyun Yao; Hourong Cai; Yong Song
Journal:  Biochem Biophys Res Commun       Date:  2013-10-14       Impact factor: 3.575

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  13 in total

1.  LncRNA LINC00152 promoted glioblastoma progression through targeting the miR-107 expression.

Authors:  Xinzhi Liu; Yimamu Yidayitula; Heng Zhao; Yi Luo; Xiaoqiang Ma; Minhua Xu
Journal:  Environ Sci Pollut Res Int       Date:  2018-04-18       Impact factor: 4.223

2.  MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.

Authors:  Lixia Wang; Jingna Su; Zhe Zhao; Yingying Hou; Xuyuan Yin; Nana Zheng; Xiuxia Zhou; Jingzhe Yan; Jun Xia; Zhiwei Wang
Journal:  Cell Cycle       Date:  2017-09-12       Impact factor: 4.534

3.  Chemotherapy-Induced Long Non-coding RNA 1 Promotes Metastasis and Chemo-Resistance of TSCC via the Wnt/β-Catenin Signaling Pathway.

Authors:  Zhaoyu Lin; Lijuan Sun; Shule Xie; Shanyi Zhang; Song Fan; Qunxing Li; Weixiong Chen; Guokai Pan; Weiwei Wang; Bin Weng; Zhang Zhang; Bodu Liu; Jinsong Li
Journal:  Mol Ther       Date:  2018-04-05       Impact factor: 11.454

4.  Stromal SPOCK1 supports invasive pancreatic cancer growth.

Authors:  Veronique L Veenstra; Helene Damhofer; Cynthia Waasdorp; Anne Steins; Hemant M Kocher; Jan P Medema; Hanneke W van Laarhoven; Maarten F Bijlsma
Journal:  Mol Oncol       Date:  2017-06-05       Impact factor: 6.603

Review 5.  Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy.

Authors:  Xiao Zhao; Rujing Chen; Mei Liu; Jianfang Feng; Jun Chen; Kaili Hu
Journal:  Acta Pharm Sin B       Date:  2017-09-01       Impact factor: 11.413

6.  SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.

Authors:  Xiaowei Zheng; Changwei Wang; Yuanming Xing; Siying Chen; Ti Meng; Haisheng You; Iwao Ojima; Yalin Dong
Journal:  Int J Oncol       Date:  2017-02-10       Impact factor: 5.650

7.  SPOCK1 is a novel inducer of epithelial to mesenchymal transition in drug-induced gingival overgrowth.

Authors:  Rehab Alshargabi; Tomomi Sano; Akiko Yamashita; Aiko Takano; Taiki Sanada; Misaki Iwashita; Takanori Shinjo; Takao Fukuda; Terukazu Sanui; Shosei Kishida; Fusanori Nishimura
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

8.  Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.

Authors:  Ming-Hsien Chien; Yung-Wei Lin; Yu-Ching Wen; Yi-Chieh Yang; Michael Hsiao; Junn-Liang Chang; Hsiang-Ching Huang; Wei-Jiunn Lee
Journal:  J Exp Clin Cancer Res       Date:  2019-06-10

9.  Multiomic analysis of the function of SPOCK1 across cancers: an integrated bioinformatics approach.

Authors:  Jie Han; Yihui Rong; Xudong Gao
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

Review 10.  SPOCK1 Involvement in Epithelial-to-Mesenchymal Transition: A New Target in Cancer Therapy?

Authors:  Li-Rui Sun; Si-Yu Li; Qiu-Shi Guo; Wei Zhou; Hong-Mei Zhang
Journal:  Cancer Manag Res       Date:  2020-05-18       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.